Generic EpiPen Pricing Parity and Less than 1% Share Supports $10 Adamis (ADMP) Target Price - Maxim Group
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
After surging 25% on Friday as investors focused on the company's PFS an alternative to EpiPen, Adamis Pharmaceuticals (NASDAQ: ADMP) is down 15% Monday as Mylan (NYSE: MYL) announced the launch of a generic version for a list price of $300 per two-pack carton, a 50% saving.
Commenting on Adamis amid the news, Maxim Group analyst Jason Kolbert said price parity with existing generics at time of launch and modest share (less than 1%) of the market the first few years support their $10 price target. Although they expect Adamis' market share could actually be much greater.
Kolbert explains that what is causing EpiPen to be expensive is not the epinephrine, which treats life-threatening anaphylaxis, but the auto injector, a delivery mechanism that can precisely inject a single 0.3-mL dose of 1:1000 epinephrine into muscle. He notes it has been reported that some consumers purchase epinephrine and self-inject with a common syringe to save on cost.
"We believe this could create an opportunity for Adamis to acquire market share with a price competitive and superior product," he said. "Adamis has developed an epinephrine Pre-filled Syringe (PFS) comparable to EpiPen. It is an epinephrine injection USP 1:1000, 0.3mg pre-filled single dose syringe. We have evaluated the device and find it in many ways to be preferable to EpiPen, in size, shape and overall function; price may be a strategic advantage too."
In June, Adamis' PFS a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for the PFS product. Adamis has outlined the steps needed to resubmit the NDA. They believe there is nothing extraordinary in the steps and see PFS as close to approval now, with data submission by year-end or early 1Q17.
The firm reiterated a Buy rating and price target of $10.
Shares of Adamis Pharmaceuticals closed at $3.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rite Aid (RAD)/Walgreens (WBA) Antitrust Concerns Doesn't Mean Deal is Dead, Says Deutsche Bank
- Citron Research Negative on TransDigm Group (TDG) amid Trump Era; Calls Valeant of Aerospace
- Transgenomic (TBIO) Climbs to Session High, Up 35%
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Momentum Movers, Trader Talk
Related EntitiesMaxim Group, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!